Ratings Quest Diagnostics Incorporated

Equities

DGX

US74834L1008

Market Closed - Nyse Other stock markets 04:00:02 2024-04-17 pm EDT			5-day change	1st Jan Change
127 ^USD	-0.35%		-3.53%	-7.91%

Apr. 11	John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission	CI
Apr. 05	Quest Diagnostics Receives Shareholder Proposal from John Chevedden	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
QUEST DIAGNOSTICS INCORPORATED	-7.91%	14.1B		A-
HCA HEALTHCARE, INC.	+14.91%	82.27B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.06%	29.43B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.02%	16.82B		B
FRESENIUS SE & CO. KGAA	-4.99%	15.89B		A-
EUROFINS SCIENTIFIC SE	+0.17%	12.05B		A-
PURE HEALTH HOLDING	-29.65%	12.01B	-	-
DAVITA INC.	+21.84%	11.19B		B-
FRESENIUS MEDICAL CARE AG	-5.85%	11.09B		A-
NATERA, INC.	+44.20%	10.91B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes